Key Findings

1. Who leads? Effexor XR is the leader in tier 1 and 2 availability for commercial plans with just under 90% availability. Effexor XR's formulary access has been steady over the past 17 months.
2. Who gained ground? Cymbalta's availability increased steadily from 19% in July 2006 to 34% in November 2007.
3. Who lost ground? As a result of patent expirations, Effexor and Zoloft both experienced a rapid and significant decline in tier 1 and 2 availability. Effexor's availability declined from 81% in July 2006 to 19% in November 2007. Zoloft's availability declined from 75% in July 2006 to 11% in November 2007. The availability of Paxil CR on tiers 1 and 2 also declined during the study period, ending November 2007 at 48%, down from 59% in 2006.

Printable version

Lack of Impact from Two Key Generics in the Anti-depressant Formulary Market (PDF 296KB)

Archives

December 2007: Lack of Impact from Two Key Generics in the Anti-depressant Formulary Market

October 2007: Formulary Position Differences between Commercial and Medicare Plans

September 2007: Impact of Patent Loss for Zocor on the Statin Marketplace